Fractyl Health Revita Securities Fraud Class Action
Analysis based on 80 articles · First reported Aug 22, 2026 · Last updated Sep 22, 2026
The lawsuit and the sharp share-price collapse keep negative pressure on Fractyl Health's equity and raise its litigation and reputational risk, while the case is largely idiosyncratic and unlikely to move broad market indices. It reinforces scrutiny of clinical-trial disclosure practices across small-cap biotech, a modest sentiment negative for the sector.
Multiple investor-rights law firms have filed and are publicizing a securities class action against Fractyl Health, Inc. (NASDAQ: GUTS) and certain of its officers in the United States — United States District Court for the Southern District of New York. The complaint alleges that during the Class Period of January 13, 2025 to January 29, 2026, defendants made materially false and misleading statements about the company's Revita DMR System and the REMAIN-1 Midpoint Cohort. Specifically, the suit claims Revita was less effective than represented and that operational issues at one of the six REMAIN-1 Midpoint Cohort clinical sites compromised the integrity of efficacy results, overstating Revita's clinical, regulatory, and commercial prospects. On January 29, 2026, Fractyl reported six-month data showing 4.5% weight regain in Revita-treated patients versus 7.5% in the sham arm, and CEO Harith Rajagopalan reportedly attributed part of the disappointing result to a site with higher-than-expected regain across both arms. Fractyl shares reportedly fell about 68% to $0.58 on January 29, 2026, and a further 21% to $0.46 on January 30, 2026. Law firms including Bronstein, Gewirtz & Grossman, LLC, Glancy Prongay & Murray, Robbins LLP, Levi & Korsinsky, and the Law Offices of Frank R. Cruz are soliciting investors, with an October 20, 2026 lead plaintiff deadline. Analysts at Canaccord Genuity and Morgan Stanley have weighed in, with Morgan Stanley reportedly cutting its Revita probability of success from 50% to 35% and its price target from $8.00 to $2.00.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard